Rebekah TuchschererFusing a small protein to a natural blood clotting factor made the factor last significantly longer in the human body, according to a new clinical study that has raised hopes for a vastly improved treatment for hemophilia.
Currently, people with severe forms of hemophilia—a condition in which blood fails to clot properly—often infuse themselves at home with the clotting factor three to four times a week to prevent bleeding; the new fusion protein could decrease those treatments to just once a week.The therapy, which includes an experimental fusion protein named BIVV001, still hasn’t been shown to stop bleeding in hemophilia patients in a large-scale clinical trial, but the extended duration of the clotting factors has.